November 1, 2010

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

.   .   

This study assessed the relationship between initial responsiveness to darbepoetin alfa and outcomes in patients with chronic kidney disease and type 2 diabetes mellitus. A poor initial hematopoietic response was associated with an increased risk of death or cardiovascular events.

Related Articles:

Anemia, Chronic Kidney Disease
  • Douglas Pitre

    The issue that seems to be somewhat”overlooked”
    involves the administartion of darbepoetin in patients with anemia of chronic disease with low calculated iron saturation (1500). Many physicians do not feel comforttable giving IV iron under these conditions or to patients at risk for serious ID issues, BUT feel “obligated” to use erythropoetic agents. Is there any merit or evidence that these agents should be used or have shown benefit in these functional iron deficiency states? Should darbepoetin therapy be withheld until iron status can be improved? We can see the possible waste of helath care rescources and now the possble adverse effects escalating doses in this type of patient.